BG105214A - Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders - Google Patents
Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disordersInfo
- Publication number
- BG105214A BG105214A BG105214A BG10521401A BG105214A BG 105214 A BG105214 A BG 105214A BG 105214 A BG105214 A BG 105214A BG 10521401 A BG10521401 A BG 10521401A BG 105214 A BG105214 A BG 105214A
- Authority
- BG
- Bulgaria
- Prior art keywords
- glucocorticoid
- receptor ligands
- treatment
- hormone receptor
- metabolic disorders
- Prior art date
Links
- 108090000079 Glucocorticoid Receptors Proteins 0.000 title abstract 3
- 108090000721 thyroid hormone receptors Proteins 0.000 title abstract 3
- 239000003446 ligand Substances 0.000 title abstract 2
- 102000004217 thyroid hormone receptors Human genes 0.000 title abstract 2
- 102100033417 Glucocorticoid receptor Human genes 0.000 title 1
- 208000030159 metabolic disease Diseases 0.000 title 1
- 102000003676 Glucocorticoid Receptors Human genes 0.000 abstract 2
- 125000001931 aliphatic group Chemical group 0.000 abstract 2
- -1 alkenyl carboxylic acid Chemical class 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 239000003862 glucocorticoid Substances 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 230000004060 metabolic process Effects 0.000 abstract 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/78—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C217/80—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings
- C07C217/82—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring
- C07C217/90—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton having amino groups and etherified hydroxy groups bound to carbon atoms of non-condensed six-membered aromatic rings of the same non-condensed six-membered aromatic ring the oxygen atom of at least one of the etherified hydroxy groups being further bound to a carbon atom of a six-membered aromatic ring, e.g. amino-diphenylethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/56—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having carbon atoms of carboxamide groups bound to carbon atoms of carboxyl groups, e.g. oxamides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
- C07C59/64—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings
- C07C59/66—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings
- C07C59/68—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings the non-carboxylic part of the ether containing six-membered aromatic rings the oxygen atom of the ether group being bound to a non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/32—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
- C07C65/40—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups containing singly bound oxygen-containing groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
- C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
- C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9816935.2A GB9816935D0 (en) | 1998-08-05 | 1998-08-05 | Novel glucocortoid and thyroid receptor ligands for the treatment of metabolic disorders |
| PCT/IB1999/001447 WO2000007972A1 (en) | 1998-08-05 | 1999-08-04 | Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BG105214A true BG105214A (en) | 2001-12-29 |
Family
ID=10836671
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG105214A BG105214A (en) | 1998-08-05 | 2001-02-02 | Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6492424B1 (enExample) |
| EP (1) | EP1102739B1 (enExample) |
| JP (1) | JP2002522407A (enExample) |
| KR (1) | KR20010072113A (enExample) |
| CN (1) | CN1311767A (enExample) |
| AT (1) | ATE238267T1 (enExample) |
| AU (1) | AU753376B2 (enExample) |
| BG (1) | BG105214A (enExample) |
| BR (1) | BR9912742A (enExample) |
| CA (1) | CA2339194A1 (enExample) |
| DE (1) | DE69907210T2 (enExample) |
| DK (1) | DK1102739T3 (enExample) |
| ES (1) | ES2193730T3 (enExample) |
| GB (1) | GB9816935D0 (enExample) |
| HU (1) | HUP0103222A3 (enExample) |
| ID (1) | ID28805A (enExample) |
| IL (1) | IL141106A0 (enExample) |
| MX (1) | MXPA01001047A (enExample) |
| NO (1) | NO20010610L (enExample) |
| PL (1) | PL345824A1 (enExample) |
| SE (1) | SE1102739T5 (enExample) |
| SI (1) | SI20579A (enExample) |
| SK (1) | SK942001A3 (enExample) |
| TR (1) | TR200100274T2 (enExample) |
| WO (1) | WO2000007972A1 (enExample) |
| ZA (1) | ZA200100832B (enExample) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL144765A0 (en) * | 1999-03-01 | 2002-06-30 | Pfizer Prod Inc | Oxamic acids and derivatives as thyroid receptor ligands |
| US6599942B1 (en) | 1999-03-29 | 2003-07-29 | Novartis Ag | Thyromimetic organic compounds |
| US6790978B2 (en) | 1999-03-29 | 2004-09-14 | Novartis Ag | Thyromimetic organic compounds |
| GB9928805D0 (en) * | 1999-12-07 | 2000-02-02 | Karobio Ab | Compounds active at the Glucocorticoid and Thyroid Hormone Receptors |
| US6664291B2 (en) | 2000-03-31 | 2003-12-16 | Pfizer, Inc. | Malonamic acids and derivatives thereof as thyroid receptor ligands |
| DE10038007A1 (de) * | 2000-08-04 | 2002-02-14 | Bayer Ag | Neue Amino-und Amido-Diphenylether für Arzneimittel |
| EP1201660B1 (en) | 2000-10-30 | 2005-08-31 | Pfizer Products Inc. | Glucocorticoid receptor modulators |
| WO2002040018A1 (en) * | 2000-11-14 | 2002-05-23 | Alcon, Inc. | Treatment of glaucoma and ocular hypertension |
| GB0029100D0 (en) * | 2000-11-29 | 2001-01-10 | Karobio Ab | Compounds active at the glucocorticoid receptor |
| GB0029102D0 (en) * | 2000-11-29 | 2001-01-10 | Karobio Ab | Compounds active at the glucocorticoid receptor |
| US6583180B2 (en) | 2001-02-14 | 2003-06-24 | Abbott Laboratories | Glucocorticoid receptor modulators |
| US6777442B2 (en) * | 2001-03-12 | 2004-08-17 | Bayer Aktiengesellschaft | Diphenyl derivatives |
| GB0111861D0 (en) | 2001-05-15 | 2001-07-04 | Karobio Ab | Novel compounds |
| GB0120691D0 (en) * | 2001-08-24 | 2001-10-17 | Karobio Ab | Novel Compounds |
| KR20040027927A (ko) | 2001-08-24 | 2004-04-01 | 카로 바이오 아베 | 심장 및 대사 장애의 치료를 위해 주요 환이 치환된갑상선 수용체 길항근 |
| EP1430017A2 (en) | 2001-09-26 | 2004-06-23 | Theravance, Inc. | Substituted phenol compounds useful for anesthesia and sedation |
| ATE313325T1 (de) | 2001-09-26 | 2006-01-15 | Pfizer Prod Inc | Indolcaroboxylsäure als thyroidrezeptor-liganden |
| AU2003214879B2 (en) | 2002-01-22 | 2008-02-07 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
| EP1471049A4 (en) | 2002-01-30 | 2006-08-16 | Kissei Pharmaceutical | NEW THYROIDIAN HORMONE RECEPTOR LIGAND, MEDICINAL PREPARATIONS CONTAINING THE SAME AND USE THEREOF |
| GB0215978D0 (en) * | 2002-07-10 | 2002-08-21 | Karobio Ab | Novel compounds |
| AU2002951977A0 (en) | 2002-10-10 | 2002-10-24 | Leo Engineering Pty Ltd | Improvements to two-part vessels |
| US7829552B2 (en) | 2003-11-19 | 2010-11-09 | Metabasis Therapeutics, Inc. | Phosphorus-containing thyromimetics |
| GB0406378D0 (en) * | 2004-03-22 | 2004-04-21 | Karobio Ab | Novel pharmaceutical compositions |
| EP1890768A2 (en) * | 2005-05-26 | 2008-02-27 | Metabasis Therapeutics, Inc. | Novel phosphinic acid-containing thyromimetics |
| MX2007014502A (es) | 2005-05-26 | 2008-02-07 | Metabasis Therapeutics Inc | Tiromimeticos para el tratamiento de enfermedades del higado graso. |
| EP2273881A1 (en) * | 2008-04-15 | 2011-01-19 | Osteogenex, Inc. | Compounds and methods for altering bone growth |
| EP3541395A4 (en) | 2016-11-21 | 2020-07-01 | Viking Therapeutics, Inc. | GLYCOGENOSIS TREATMENT METHODS |
| KR102600115B1 (ko) | 2017-06-05 | 2023-11-09 | 바이킹 테라퓨틱스 인코포레이티드 | 섬유증 치료를 위한 조성물 |
| WO2019183004A1 (en) | 2018-03-22 | 2019-09-26 | Viking Therapeutics, Inc. | Crystalline forms and methods of producing crystalline forms of a compound |
| US12102646B2 (en) | 2018-12-05 | 2024-10-01 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis and inflammation |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0580550B1 (en) * | 1992-07-21 | 1997-10-22 | Novartis AG | Oxamic acid derivatives as hypocholesteremic agents |
| WO1999063976A2 (en) * | 1998-06-08 | 1999-12-16 | Karo Bio Ab | Liver-selective glucocorticoid antagonist for treating diabetes |
-
1998
- 1998-08-05 GB GBGB9816935.2A patent/GB9816935D0/en not_active Ceased
-
1999
- 1999-08-04 DK DK99936913T patent/DK1102739T3/da active
- 1999-08-04 SE SE99936913T patent/SE1102739T5/xx unknown
- 1999-08-04 AU AU51881/99A patent/AU753376B2/en not_active Ceased
- 1999-08-04 JP JP2000563607A patent/JP2002522407A/ja active Pending
- 1999-08-04 CA CA002339194A patent/CA2339194A1/en not_active Abandoned
- 1999-08-04 MX MXPA01001047A patent/MXPA01001047A/es not_active IP Right Cessation
- 1999-08-04 KR KR1020017001279A patent/KR20010072113A/ko not_active Withdrawn
- 1999-08-04 CN CN99809310A patent/CN1311767A/zh active Pending
- 1999-08-04 WO PCT/IB1999/001447 patent/WO2000007972A1/en not_active Ceased
- 1999-08-04 BR BR9912742-3A patent/BR9912742A/pt not_active Application Discontinuation
- 1999-08-04 DE DE69907210T patent/DE69907210T2/de not_active Expired - Fee Related
- 1999-08-04 IL IL14110699A patent/IL141106A0/xx unknown
- 1999-08-04 ES ES99936913T patent/ES2193730T3/es not_active Expired - Lifetime
- 1999-08-04 SI SI9920064A patent/SI20579A/sl unknown
- 1999-08-04 TR TR2001/00274T patent/TR200100274T2/xx unknown
- 1999-08-04 PL PL99345824A patent/PL345824A1/xx not_active Application Discontinuation
- 1999-08-04 EP EP99936913A patent/EP1102739B1/en not_active Expired - Lifetime
- 1999-08-04 SK SK94-2001A patent/SK942001A3/sk unknown
- 1999-08-04 US US09/744,865 patent/US6492424B1/en not_active Expired - Fee Related
- 1999-08-04 ID IDW20010257A patent/ID28805A/id unknown
- 1999-08-04 AT AT99936913T patent/ATE238267T1/de not_active IP Right Cessation
- 1999-08-04 HU HU0103222A patent/HUP0103222A3/hu unknown
-
2001
- 2001-01-30 ZA ZA200100832A patent/ZA200100832B/xx unknown
- 2001-02-02 BG BG105214A patent/BG105214A/xx unknown
- 2001-02-05 NO NO20010610A patent/NO20010610L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL345824A1 (en) | 2002-01-14 |
| EP1102739A1 (en) | 2001-05-30 |
| ES2193730T3 (es) | 2003-11-01 |
| DE69907210T2 (de) | 2004-02-19 |
| NO20010610D0 (no) | 2001-02-05 |
| CN1311767A (zh) | 2001-09-05 |
| SE1102739T3 (enExample) | 2003-08-12 |
| KR20010072113A (ko) | 2001-07-31 |
| DK1102739T3 (da) | 2003-08-18 |
| ZA200100832B (en) | 2001-10-31 |
| AU5188199A (en) | 2000-02-28 |
| TR200100274T2 (tr) | 2001-09-21 |
| US6492424B1 (en) | 2002-12-10 |
| HUP0103222A2 (hu) | 2002-01-28 |
| HUP0103222A3 (en) | 2002-12-28 |
| DE69907210D1 (de) | 2003-05-28 |
| CA2339194A1 (en) | 2000-02-17 |
| NO20010610L (no) | 2001-04-04 |
| EP1102739B1 (en) | 2003-04-23 |
| SI20579A (sl) | 2001-12-31 |
| AU753376B2 (en) | 2002-10-17 |
| WO2000007972A1 (en) | 2000-02-17 |
| JP2002522407A (ja) | 2002-07-23 |
| SK942001A3 (en) | 2001-12-03 |
| GB9816935D0 (en) | 1998-09-30 |
| BR9912742A (pt) | 2001-05-02 |
| ATE238267T1 (de) | 2003-05-15 |
| SE1102739T5 (enExample) | 2003-09-16 |
| ID28805A (id) | 2001-07-05 |
| IL141106A0 (en) | 2002-02-10 |
| MXPA01001047A (es) | 2002-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG105214A (en) | Glucocorticoid and thyroid hormone receptor ligands for the treatment of metabolic disorders | |
| CA2294098A1 (en) | Novel thyroid receptor ligands and method | |
| NZ512422A (en) | Novel thyroid receptor ligands and method II | |
| Hansen et al. | Glucagon-like peptide-1-(7–36) amide is transformed to glucagon-like peptide-1-(9–36) amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine | |
| MY140525A (en) | Pharmaceutical uses for alpha2delta ligands | |
| KR950702829A (ko) | 신경계 퇴행성 질환의 치료에 유용한 아나바세인 유도체 | |
| CZ85395A3 (en) | Derivatives of vaprooic and 1-valproenic acids and pharmaceutical preparations based thereon | |
| FR2697252B1 (fr) | Dérivés de 1,2,3,5,6,7,8,8a-octahydro-5,5,8a-triméthyl-(8abeta)-6-isoquinolineamine, leur procédé de préparation et leur utilisation en thérapeutique. | |
| AU2251901A (en) | Methods and compounds for inhibiting MRP1 | |
| WO1999016791A3 (en) | Compounds and methods for regulating cell adhesion | |
| MY135821A (en) | Therapeutic agents | |
| WO2004066929A3 (en) | Cycloalkyl containing anilide ligands for the thyroid receptor | |
| TW200507836A (en) | Therapeutic agents | |
| CA2053820A1 (en) | Method of Inhibiting Metabolism of Cholesterol | |
| GB0215978D0 (en) | Novel compounds | |
| DE69905877D1 (de) | Substanzen, die mit dem thyroid-hormonrezeptor interagieren, zur behandlung fibrotischer erkrankungen | |
| HK95697A (en) | 5-HT1-like receptor agonist for rectal administration | |
| HUT64309A (en) | Process for production pharmaceutical preparations having benzazepine compounds as effective substance and the new effective substance | |
| Pries et al. | Taurocholate is more potent than cholate in suppression of bile salt synthesis in the rat | |
| GB9907048D0 (en) | Novel glucocorticoid receptor ligands for the treatment of meta bolic disorders | |
| ZA961044B (en) | New pyridine and pyridazine derivatives, processes for the production thereof and pharmaceutical agents containing these compounds. | |
| WO1995005364A3 (en) | Inhibitors of biogenic amine transporters | |
| AU2224795A (en) | Ameliorant or remedy for paraneoplastic syndrome | |
| Kroger et al. | Induction of tyrosine aminotransferase under the influence of D-galactosamine | |
| Gourdji et al. | Effects of VIP on prolactin and growth hormone secretion by GH cells. regulation by peripheral hormone |